The FDA has approved Merck's Enflonsia (clesrovimab), a monoclonal antibody for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants under 12 months. This approval introduces a competitor to Sanofi and AstraZeneca's Beyfortus. However, the CDC’s Advisory Committee on Immunization Practices (ACIP), which advises on vaccine use, has been completely dismissed by HHS Secretary Robert F. Kennedy Jr., causing uncertainty around vaccine recommendations and public health policymaking. The upcoming ACIP meeting scheduled for June 25-27 will occur under a reconstituted committee.